Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sumitomo Pharma CoDNPUF 65 EV-to-FCF is 10.95 as of Jul. 25, 2026, which is 8% below its 10-year median of 11.90. GuruFocus rates DNPUF with a GF Score™ of 65/100 and a GF Value™ of $5.51 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 568 Drug Manufacturers companies, Sumitomo Pharma Co ranks better than 73.77% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sumitomo Pharma Co's Enterprise Value is $4,539 Mil.
Sumitomo Pharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $414 Mil. Therefore, Sumitomo Pharma Co's EV-to-FCF for today is 10.95.
The historical rank and industry rank for Sumitomo Pharma Co's EV-to-FCF or its related term are showing as below:
DNPUF'
s EV-to-FCF Range Over the Past 10 Years
Min: -632.54 Med: 11.9 Max: 197.64
Current: 11.55
During the past 13 years, the highest EV-to-FCF of Sumitomo Pharma Co was 197.64. The lowest was -632.54. And the median was 11.90.
DNPUF's EV-to-FCF is ranked better than 73.77% of 568
companies
in the Drug Manufacturers industry
Industry Median: 21.015
vs DNPUF: 11.55
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sumitomo Pharma Co (OTCPK:DNPUF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sumitomo Pharma Co's PE Ratio (TTM) for today is calculated as:
Sumitomo Pharma Co's share price for today is $8.405.
Sumitomo Pharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.816.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sumitomo Pharma Co EV-to-FCF Related Terms
Sumitomo Pharma Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Sumitomo Pharma Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sumitomo Pharma Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sumitomo Pharma Co's EV-to-FCF falls into.
Sumitomo Pharma Co's current Enterprise Value is $4,539 Mil.
Sumitomo Pharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $414 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sumitomo Pharma Co (DNPUF) has a EV-to-FCF of 10.95 as of Jul. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sumitomo Pharma Co and its competitors. This is near median its historical median of 11.90. According to the industry distribution chart, Sumitomo Pharma Co ranks #149 out of 568 companies in the Drug Manufacturers industry, placing it in the top 26.2%.
Is Sumitomo Pharma Co's EV-to-FCF too high?
Sumitomo Pharma Co's current EV-to-FCF of 10.95 is near median its 10-year median of 11.90. The Drug Manufacturers industry median EV-to-FCF is 21.02. Sumitomo Pharma Co's value of 10.95 is 47.9% below this industry median. Based on the distribution chart, Sumitomo Pharma Co ranks #149 out of 568 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sumitomo Pharma Co has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sumitomo Pharma Co ranks #149 out of 568 companies for EV-to-FCF. This puts Sumitomo Pharma Co in the upper half of its industry. The industry median EV-to-FCF is 21.02. Sumitomo Pharma Co's value of 10.95 is 47.9% below this benchmark. While the company's 10-year median is 11.90 vs. the industry median of 21.02, Sumitomo Pharma Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.02, based on 568 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sumitomo Pharma Co's current EV-to-FCF of 10.95 is 47.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sumitomo Pharma Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sumitomo Pharma Co's current EV-to-FCF is 10.95, which is near median its own 10-year median of 11.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (DNPUF) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.51, compared to a current price of $8.41 — trading 52.5% above its estimated fair value. The current EV-to-FCF is 10.95, which is near median its 10-year median of 11.90 and 47.9% below the Drug Manufacturers industry median of 21.02. Sumitomo Pharma Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sumitomo Pharma Co (DNPUF), the current EV-to-FCF is 10.95 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sumitomo Pharma Co (DNPUF) Overvalued in 2026?
Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued.
The current stock price of $8.41 is trading 52.5% above its estimated GF Value™ of $5.51.
GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.
Key valuation signals for DNPUF:
EV-to-FCF: 10.95 (near median its 10-year median of 11.90)
GF Value™: $5.51 vs. price of $8.41 (52.5% above fair value)
Industry Position: 47.9% below the Drug Manufacturers median (#149 of 568)
No single metric tells the full story. See the DNPUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
65GF Score
Get the complete analysis for DNPUF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNPUF has been successfully added to your 
